Below are current clinical trials.3 studies in Biological therapy for cancer
(open studies only).
Filter this list of studies by location, status and more.
To investigate the efficacy of autologous Epstein-barr virus (EBV)-specific T cells for the treatment of EBV positive Diffuse Large B Cell Lymphoma (DLBCL), Hodgkin Lymphoma (HL) and Post-transplant Lymphoproliferative Disease (PTLD) after failing first line treatment.
This randomized phase III trial studies rituximab and yttrium Y-90 ibritumomab tiuxetan to see how well they work compared to rituximab alone in treating patients with untreated follicular lymphoma. Monoclonal antibodies, such as rituximab, may find cancer cells and help kill them. Radioactive substances linked to monoclonal antibodies can bind to cancer cells and give off radiation which may help kill cancer cells. It is not yet known whether rituximab is more effective with or without yttrium Y-90 ibritumomab tiuxetan in treating follicular lymphoma.
This partially randomized phase III clinical trial is studying different combinations of risk-adapted chemotherapy regimens and their side effects and comparing how well they work in treating younger patients with newly diagnosed standard-risk acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy), giving the drugs in different doses, and giving the drugs in different combinations may kill more cancer cells.
Nov. 21, 2017
- De Vita VT Jr, et al., eds. Cancer immunotherapy. In: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th ed. Philadelphia, Pa.: Wolters Kluwer Health Lippincott Williams & Wilkins; 2015. http://www.ovid.com/site/index.jsp. Accessed Oct. 9, 2017.
- Biological therapies for cancer. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/bio-therapies-fact-sheet. Accessed Oct. 9, 2017.
- Niederhuber JE, et al., eds. Therapeutic antibodies and immunologic conjugates. In: Abeloff's Clinical Oncology. 5th ed. Philadelphia, Pa.: Churchill Livingstone Elsevier; 2014. https://www.clinicalkey.com. Accessed Oct. 9, 2017.
- Shah DJ, et al. Latest advances in chemotherapeutic, targeted and immune approaches in the treatment of metastatic melanoma. Mayo Clinic Proceedings. 2014;89:504.
Biological therapy for cancer